Keyphrases
Sunitinib
100%
Metastatic Renal Cell Carcinoma (mRCC)
85%
Single nucleotide Polymorphism
44%
Pharmacogenetics
30%
Pharmacokinetics
30%
Overall Survival
29%
Genetic Variants
28%
Pediatric Oncology
27%
Genetic Polymorphism
25%
Progression-free Survival
24%
Inhibitor Formulations
23%
Age-appropriate Dosage Form
23%
Chemotherapy Toxicity
23%
Kinase Inhibitor
23%
Pediatric Cancer Patients
23%
Tyrosine Kinase Inhibitor
19%
Induced Toxicity
17%
Cytochrome P450 3A4 (CYP3A4)
15%
SU12662
14%
Targeted Therapy
14%
Association Analysis
14%
Pharmacokinetics-pharmacodynamics (PK-PD)
13%
Clinical Outcomes
13%
Clinical Practice
12%
Confidence Interval
12%
Clear-cell Metastatic Renal Cell Carcinoma
11%
Efficacy Outcomes
11%
Down Syndrome Cell Adhesion Molecule (DSCAM)
11%
CYP3A5 Polymorphism
11%
Genome-wide Meta-analysis
11%
Collaborative Projects
11%
Induced Hypertension
11%
Population Modeling
11%
Tumor Biomarkers
11%
Pharmacogenomics
11%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
11%
Interleukin-13 (IL-13)
11%
PDLIM3
11%
ABCB1 Polymorphism
11%
Renal Cell
11%
Pharmacogenetic Testing
11%
Propofol Dose
10%
Treatment Outcome
9%
Meta-analysis
9%
Anticancer Drugs
8%
T Allele
7%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
7%
Dose Reduction
7%
Clinical Benefit
7%
ATP Binding Cassette Subfamily B Member 1 (ABCB1)
7%
Pharmacology, Toxicology and Pharmaceutical Science
Sunitinib
99%
Kidney Metastasis
71%
Pharmacokinetics
45%
Malignant Neoplasm
41%
Overall Survival
30%
Childhood Cancer
29%
Biological Marker
27%
Chemotherapy
26%
Progression Free Survival
25%
Phosphotransferase Inhibitor
23%
Dosage Forms
23%
Protein Tyrosine Kinase Inhibitor
22%
Pharmacodynamics
20%
Pharmacogenetics
19%
CYP3A4
17%
Neoplasm
16%
Cytochrome P450 3A5
15%
N Deethylsunitinib
13%
Pharmacogenomics
11%
Cytotoxic T Lymphocyte Antigen 4
11%
Propofol
11%
Acute Lymphoblastic Leukemia
11%
Event Free Survival
9%
Vasculotropin Receptor
6%
Renal Cell Carcinoma
6%
Biochemistry, Genetics and Molecular Biology
Sunitinib
77%
Cancer Cell
37%
Single-Nucleotide Polymorphism
34%
Overall Survival
32%
Genetic Polymorphism
25%
Progression Free Survival
21%
Pharmacokinetics
18%
Tyrosine Kinase Inhibitor
18%
Genetic Divergence
18%
Pharmacogenetics
18%
CYP3A5
15%
High Risk Population
13%
Observational Study
13%
Down Syndrome Cell Adhesion Molecule
11%
CTLA-4
11%
Pharmacogenomics
11%
Pharmacogenetic Testing
11%
Allele
9%
Anticancer
8%
Genetics
8%
Patient Coding
7%
Pharmacodynamics
6%
Germline
6%
Germ Cell
6%
Drug Dose Reduction
6%
Exome Sequencing
5%
Haplotype
5%